Douglas J. Anderson, M.D., M.S., associate professor in the Division of Transplantation in the UAB Department of Surgery, has been selected to serve on the Editorial Board of the Journal of Surgical Research (JSR), a leading peer-reviewed journal dedicated to advancing scientific discovery and academic surgery.
JSR is the official journal of the Association for Academic Surgery and serves as an international forum for high-quality basic, translational, and clinical surgical research. The journal currently holds an impact factor of approximately 1.7, a five-year impact factor of 2.0, and an h-index of 131, reflecting its sustained scholarly influence and citation impact within the surgical research community. Its editorial board is composed of nationally recognized surgeon-scientists selected for their scholarly expertise, commitment to rigorous peer review, and contributions to advancing the field of surgery.
Anderson will serve a three-year term through December 31, 2028.
“I am deeply honored to join the Editorial Board of the JSR,” Anderson said. “JSR has long played a vital role in promoting innovation and supporting surgeon-scientists at all stages of their careers. I look forward to contributing to the journal’s mission and helping ensure the continued excellence of surgical research.”
Anderson serves as director of pancreas transplantation and program director of the UAB Abdominal Transplant Fellowship. He also holds key leadership roles in kidney transplantation and is actively involved in clinical care, research, and surgical education. Anderson’s academic interests center on kidney transplantation, immunosuppression, transplant rejection, and emerging applications of xenotransplantation. His work has contributed to several landmark studies in the field, including publications in JAMA Surgery and the American Journal of Transplantation that have helped advance understanding of clinical-grade porcine kidney xenotransplantation. Anderson also spent two years as a research fellow at the Emory Transplant Center, where his work focused on co-stimulation blockade–based immunosuppression strategies in preclinical kidney transplantation models.